Sana Biotechnology (SANA) announced that it has commenced an underwritten public offering of $75M of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares of common stock and pre-funded warrants to be sold in the proposed offering will be sold by Sana. Morgan Stanley, Goldman Sachs & Co., BofA Securities, and TD Cowen are acting as joint book-running managers for the proposed offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SANA:
- Promising Developments and FDA Engagement Bolster Buy Rating for Sana Biotechnology
- Sana Biotechnology announces publication on clinical data from transplantation
- Positive Outlook on Sana Biotechnology Driven by Promising T1D Program and Allogeneic CAR-T Advancements
- Sana Biotechnology assumed with an Overweight at Morgan Stanley
- Sana Biotechnology Announces Positive Diabetes Study Results